The estimated Net Worth of Andrew Schiermeier is at least $1.59 Million dollars as of 31 December 2020. Andrew Schiermeier owns over 4,792 units of Intellia Therapeutics Inc stock worth over $364,988 and over the last 7 years he sold NTLA stock worth over $0. In addition, he makes $1,227,880 as Chief Operating Officer und Executive Vice President at Intellia Therapeutics Inc.
Andrew has made over 3 trades of the Intellia Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 4,792 units of NTLA stock worth $96,990 on 31 December 2020.
The largest trade he's ever made was buying 7,500 units of Intellia Therapeutics Inc stock on 6 March 2019 worth over $117,900. On average, Andrew trades about 1,724 units every 83 days since 2018. As of 31 December 2020 he still owns at least 18,033 units of Intellia Therapeutics Inc stock.
You can see the complete history of Andrew Schiermeier stock trades at the bottom of the page.
Dr. Andrew D. Schiermeier Ph.D. serves as Chief Operating Officer, Executive Vice President of the Company. Prior to his current role, Dr. Schiermeier served as our executive vice president of corporate strategy and development since October 2018, as our executive vice president, corporate strategy from April 2018 through October 2018 and as our senior vice president, eXtellia, an Intellia division that focused on ex vivo research and development, from January 2017 through April 2018. Dr. Schiermeier has over two decades of experience as an executive in the biotechnology and pharmaceutical sectors, with experience ranging from managing operations for startups to directing the strategic expansion of global brands. From March 2013 through June 2016, Dr. Schiermeier served as senior vice president, head of oncology and general manager of the Merck-Pfizer Immuno-Oncology Alliance at Merck KGaA. From June 2016 to December 2016, Dr. Schiermeier served as an independent consultant to multiple pharmaceutical and biotechnology companies, including Verastem, Inc., Kynan Duke Pharma, LLP and Intellia. Dr. Schiermeier served as the chief operating officer of Aura Biosciences, Inc. from January 2011 through May 2013. From January 2012 through May 2013, Dr. Schiermeier was a corporate advisor to Pathogenica, Inc. Dr. Schiermeier served as the chief executive officer of Lantibio, Inc., from February 2007 through February 2008. Dr. Schiermeier served in chairman and chief executive officer roles from November 2007 through December 2014 at Medicine in Need Corp, an international not-for-profit, non-governmental organization aimed at liberating burdened populations from diseases of poverty through advanced drug and vaccine delivery. Dr. Schiermeier earned a Ph.D. in engineering and applied mathematics from Harvard University, an M.S. in bio-mechanical engineering from Stanford University and an international M.B.A. from College des Ingenieurs in Paris, France.
As the Chief Operating Officer und Executive Vice President of Intellia Therapeutics Inc, the total compensation of Andrew Schiermeier at Intellia Therapeutics Inc is $1,227,880. There are 1 executives at Intellia Therapeutics Inc getting paid more, with Laura Sepp-Lorenzino having the highest compensation of $1,762,490.
Andrew Schiermeier is 50, he's been the Chief Operating Officer und Executive Vice President of Intellia Therapeutics Inc since 2019. There are 14 older and 4 younger executives at Intellia Therapeutics Inc. The oldest executive at Intellia Therapeutics Inc is Jesse Goodman, 68, who is the Independent Director.
Andrew's mailing address filed with the SEC is C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET; SUITE 130, CAMBRIDGE, MA, 02139.
Over the last 9 years, insiders at Intellia Therapeutics Inc have traded over $210,567,884 worth of Intellia Therapeutics Inc stock and bought 1,285,277 units worth $23,117,886 . The most active insiders traders include Carl L Gordon, Jean Francois Formela und Bros. Advisors Lpbaker Feli.... On average, Intellia Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $1,357,638. The most recent stock trade was executed by Eliana Clark on 1 July 2024, trading 405 units of NTLA stock currently worth $9,287.
intellia therapeutic’s core mission is to develop curative medicines, utilizing the promise of the crispr/cas9 gene editing technology. the development of crispr/cas9 gene editing technology opens a new frontier in biomedical research and clinical intervention. adapted from a natural cellular process, crispr/cas9 permits the editing of any gene in any organism with unprecedented simplicity and flexibility. the incredible potential of this technology for treating human genetic disease inspired a group of life science veterans to create intellia therapeutics. intellia was founded in 2014 by caribou biosciences and atlas venture, along with a consortium of scientists who have helped define the space. intellia therapeutics holds exclusive access to a broad intellectual property portfolio covering the application of crispr/cas9 technology for human therapeutic use. intellia has built an experienced team of individuals to meet the challenges of bringing crispr/cas9 therapeutics to the
Intellia Therapeutics Inc executives and other stock owners filed with the SEC include: